RVG-Cys acetate

Cat. No.: HY-P5623A1

Molecular Formula: $C_{144}H_{222}N_{44}O_{44}S_3.xC_2H_4O_2$

Sequence: Tyr-Thr-Ile-Trp-Met-Pro-Glu-Asn-Pro-Arg-Pro-Gly-Thr-Pro-Cys-Asp-Ile-Phe-Thr-Asn-Ser-Arg-Gly-Lys-Arg-Ala-Ser-Asn-Gly-Cys

YTIWMPENPRPGTPCDIFTNSRGKRASNGC (acetate salt)

Sequence Shortening: YTIWMPENPRPGTPCDIFTNSRGKRASNGC

Target: RABV

Pathway: Anti-infection

Storage: Sealed storage, away from moisture and light, under nitrogen

Powder	-80°C	2 years
	-20°C	1 year

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen)

SOLVENT & SOLUBILITY

In Vitro

H_2O : ≥ 100 mg/mL

DMSO : 3.33 mg/mL (Need ultrasonic)

* "≥" means soluble, but saturation unknown.

BIOLOGICAL ACTIVITY

Description

RVG-Cys (RVG29-Cys;RDP-Cy) acetate is based on rabies virus glycoprotein (RVG29) peptide and connected to Cys to facilitate subsequent coupling[1].

REFERENCES

[1]. Yang Liu, et al. Brain-targeting gene delivery and cellular internalization mechanisms for modified rabies virus glycoprotein RVG29 nanoparticles. Biomaterials. 2009 Sep;30(25):4195-202.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA